Inclusion Criteria:

- Diagnosis of 1 of the following:

- Micropapillary or borderline (low malignant potential) ovarian tumors

- No more than 3 prior chemotherapy regimens

- Histologically or cytologically confirmed ovarian epithelial cancer, primary
peritoneal cancer, or fallopian tube cancer

- Recurrent or persistent disease despite initial platinum-based chemotherapy
(i.e., platinum-resistant disease)

- Disease progression within 6 months after completion of chemotherapy

- Received 1-3 prior chemotherapy regimens

- At least 1 regimen must have included a platinum agent
(carboplatin or cisplatin)

- Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1
dimension as ≥ 20 mm by conventional techniques or as ≥ 10 mm by spiral CT scan

- Measurable disease outside the field of prior radiotherapy OR disease
progression after completion of radiotherapy

- No known brain metastases

- ECOG performance status (PS) ≤ 2 OR Karnofsky PS ≥ 60%

- WBC ≥ 3,000/mm^3

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Bilirubin normal

- AST and ALT ≤ 2.5 times upper limit of normal

- Creatinine normal OR creatinine clearance ≥ 60 mL/min

- Not pregnant or nursing

- Fertile patients must use effective contraception

- No history of allergic reactions attributed to sulfonamides, arginine, and compounds
of similar chemical or biological composition to PXD101

- No uncontrolled intercurrent illness, including, but not limited to, any of the
following:

- Ongoing or active infection

- Psychiatric illness or social situation that would limit compliance with study
requirements

- No bowel obstruction unless receiving parenteral support

- No marked prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc
interval > 500 msec)

- No long-QT syndrome

- No significant cardiovascular disease, including any of the following:

- Unstable angina pectoris

- Uncontrolled hypertension

- Congestive heart failure related to primary cardiac disease

- Any condition requiring anti-arrhythmic therapy

- Ischemic or severe valvular heart disease

- Myocardial infarction within the past 6 months

- See Disease Characteristics

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin C)
and recovered

- At least 4 weeks since prior radiotherapy or surgery and recovered

- No prior radiotherapy to > 40% of bone marrow

- At least 2 weeks since prior valproic acid

- No concurrent medication that may cause torsades de pointes, including any of the
following:

- Disopyramide

- Dofetilide

- Ibutilide

- Procainamide

- Quinidine

- Sotalol

- Bepridil

- Amiodarone

- Arsenic trioxide

- Cisapride

- Methadone

- Lidoflazine

- Clarithromycin

- Erythromycin

- Halofantrine

- Pentamidine

- Sparfloxacin

- Domperidone

- Droperidol

- Chlorpromazine

- Haloperidol

- Mesoridazine

- Thioridazine

- Pimozide

- No other concurrent anticancer therapy

- No other concurrent investigational agents

- No concurrent combination antiretroviral therapy for HIV-positive patients